NCM
TEVA icon

Northroad Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Northroad Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.48M Sell
32,148
-38,102
-54% -$1.99M 3.37% 8
2016
Q2 		$3.53M Sell
70,250
-8,936
-11% -$476K 2.71% 15
2016
Q1 		$4.24M Sell
79,186
-5,407
-6% -$317K 2.74% 16
2015
Q4 		$5.55M Sell
84,593
-4,444
-5% -$275K 3.31% 5
2015
Q3 		$5.03M Sell
89,037
-3,696
-4% -$240K 2.96% 12
2015
Q2 		$5.48M Buy
92,733
+1,698
+2% +$105K 2.82% 13
2015
Q1 		$5.67M Sell
91,035
-44,662
-33% -$2.6M 3.03% 10
2014
Q4 		$7.8M Sell
135,697
-11,174
-8% -$623K 3.52% 4
2014
Q3 		$7.89M Sell
146,871
-9,671
-6% -$512K 3.05% 9
2014
Q2 		$8.21M Buy
156,542
+423
+0.3% +$21.6K 2.87% 13
2014
Q1 		$8.25M Buy
156,119
+29,843
+24% +$1.38M 2.99% 10
2013
Q4 		$5.06M Buy
126,276
+1,671
+1% +$65.8K 1.81% 31
2013
Q3 		$4.71M Sell
124,605
-4,716
-4% -$184K 1.81% 33
2013
Q2 		$5.07M Buy
+129,321
New +$5.04M 1.97% 31

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northroad Capital Management's TEVA Position: Q3 2016 in Review

Northroad Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 54% in Q3 2016, selling an estimated $1.99M and leaving 32,148 shares worth $1.48M. The position accounts for 3.37% of the portfolio, ranked #8.

Northroad Capital Management first reported a position in TEVA in Q2 2013 and has held it in 14 quarters since. The position peaked at $8.25M in Q1 2014. 796 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

  • Northroad Capital Management held 32,148 shares of Teva Pharmaceuticals worth $1.48M as of Q3 2016.
  • Northroad Capital Management sold 38,102 Teva Pharmaceuticals shares in Q3 2016, an estimated $1.99M.
  • Teva Pharmaceuticals made up 3.37% of Northroad Capital Management's portfolio in Q3 2016, its #8 holding.
  • Northroad Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
  • Northroad Capital Management's Teva Pharmaceuticals position peaked at $8.25M in Q1 2014.
  • 796 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Northroad Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.